Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

Troubled biotech stock Opthea (ASX:OPT), still in the process of crisis talks with investors, has flagged a workforce ...

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after ...

Australian biotech Opthea (Nasdaq: OPT) is cutting around two-thirds of its workforce, as the company moves to curb spending ...

The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ...

Fintel reports that on April 7, 2025, BELL POTTER SECURITIES downgraded their outlook for Opthea Limited - Depositary Receipt ...

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its ...

The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye ...

HC Wainwright raised their FY2025 EPS estimates for shares of Opthea in a note issued to investors on Tuesday, March 25th. HC ...

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...